Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Shivapurkar, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Shivapurkar, N.
(Chest. 2004;125:97S-101S.)
© 2004 American College of Chest Physicians

Molecular Targets for Cancer Therapy and Prevention*

Adi F. Gazdar, MD; Kuniharu Miyajima, MD; Jyotsna Reddy, MD; Ubaradka G. Sathyanarayana, PhD; Hisayuki Shigematsu, MD; Makoto Suzuki, MD, PhD; Takao Takahashi, MD and Narayan Shivapurkar, PhD

* From the University of Texas Southwestern Medical Center, Dallas, TX.

Correspondence to: Adi F. Gazdar, Hamon Center for Therapeutic Oncology Research, Department of Pathology, UT Southwestern Medical Center, Bldg NB8–206, 6000 Harry Hines Blvd, Dallas, TX, 75390-8593; e-mail: adi.Gazdar{at}utsouthwestern.edu

Despite major improvements in patient management, the prognosis for patients with lung cancer remains dismal. As our knowledge of the molecular biology of cancers has increased, new targets for therapeutic interventions have been identified. In this article, we discuss some of the more recent developments in this field. They include revisiting some of the established concepts, such as retinoid metabolism and the inhibition of cyclooxygenase-2 metabolism. In addition, newer targets, such as transforming growth factor-ß signaling, Janus-activated kinase/signal transducers and activators of transcription pathway, and cell invasion are discussed. These studies demonstrate that multiple, often overlapping, mechanisms of disruption are present in lung cancer cells, presenting a plethora of molecular targets.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Chest Physicians.